Search results
Results From The WOW.Com Content Network
Amyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), known as ALS, is a nervous system disease that affects nerve cells in the brain and spinal cord. ALS causes loss of muscle control. The disease gets worse over time.
Amyotrophic lateral sclerosis, known as ALS, can be hard to diagnose early because it can have symptoms similar to other diseases. Tests to rule out other conditions or help diagnose ALS might include:
Amyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), or ALS, is a progressive nervous system (neurological) disease that destroys nerve cells and causes disability. ALS is often called Lou Gehrig's disease, after the famous baseball player who was diagnosed with it.
This progressive nervous system disease, also known as Lou Gehrig's disease, destroys nerve cells.
Las personas con esclerosis lateral amiotrófica pueden desarrollar debilidad en los músculos que intervienen en la deglución, lo que puede derivar en malnutrición y deshidratación. También tienen mayor riesgo de que entren alimentos, líquidos o saliva en los pulmones, lo que puede causar neumonía.
This progressive nervous system disease, also known as Lou Gehrig's disease, destroys nerve cells.
Our doctors diagnose and treat more than 800 people with ALS each year. They have expertise in inherited and acquired neuromuscular conditions, genetics of myopathies present from birth (congenital) and adult-onset neuropathies, and how nerves and muscles function.
Early symptoms of Alzheimer's disease include forgetting recent events or conversations. Over time, Alzheimer's disease leads to serious memory loss and affects a person's ability to do everyday tasks. There is no cure for Alzheimer's disease.
Mayo Clinic researchers and collaborators have identified a protein expressed by immune cells that may play a key role in the development of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Mayo Clinic in Florida has received a grant to begin an innovative study that will provide hundreds of patients with amyotrophic lateral sclerosis (ALS) access to an experimental drug over six months.